ArticleOpen forum infectious diseases2026
Higher Risk of Loss to Follow-up Among Transgender People With HIV in Italy: Findings From the ICONA Cohort.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Official data on transgender people with human immunodeficiency virus (PWH) in Italy are lacking because gender identity is not recorded in national reports. We aimed to characterize transgender PWH in Italy and assess retention in care and clinical outcomes. Methods: We included PWH enrolled between 2010 and 2023 in 40 Italian Cohort Naive Antiretrovirals centers where gender identity could be reliably ascertained. Transgender PWH were compared with cisgender participants. Univariable and multivariable regression models assessed the association between gender identity and (1) loss to follow-up (LTFU; no visit or exam for ≥18 months) using Fine-Gray models and (2) a composite clinical endpoint including mortality, major adverse cardiovascular events, cancer, acquired immunodeficiency syndrome-defining events, and end-stage kidney and liver disease using Cox models. Sensitivity analyses were restricted to individuals who initiated antiretroviral therapy (ART) from 2016 onward. Results: Overall, 256 transgender and 9922 cisgender PWH were included. Transgender PWH were younger (median 32 vs 39 years, Conclusions: Transgender PWH had a substantially higher risk of LTFU than cisgender participants in this national Italian cohort. Tailored interventions are needed to improve retention and health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.